TIcaGrEloR and Absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization (TIGER-BVS trial): Rationale and study design.
Salvatore BrugalettaJosep Gomez-LaraJuan CaballeroLuis Ortega-PazLuis TeruelMiriam Jimenez FernandezRafael RomagueraVicente Alcalde MartinezMarcos ÑatoEduardo Molina NavarroJoan-Antoni Gomez-HospitalConcepcion Correa VilchesMaria JoyeraAngel CequierManel SabatePublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2017)
The TIGER BVS trial will provide the first randomized comparison between ticagrelor versus clopidogrel in recovering vascular function in CTO patients. It will also provide important data on vascular restoration therapy of Absorb BVS in this scenario.
Keyphrases
- acute coronary syndrome
- phase iii
- percutaneous coronary intervention
- clinical trial
- phase ii
- antiplatelet therapy
- end stage renal disease
- study protocol
- open label
- ejection fraction
- newly diagnosed
- chronic kidney disease
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- double blind
- patient reported outcomes
- electronic health record
- atrial fibrillation
- middle cerebral artery
- deep learning
- artificial intelligence
- data analysis